Mumbai-based Glenmark Pharmaceuticals is the first company in the world to launch Ryaltris-AZ as a novel fixed-dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg, for the treatment of moderate to severe allergic rhinitis. Recently, it has become the first company to launch the branded generic version, in the form of RyaltrisAZ Nasal Spray, at an affordable cost for the treatment of allergic rhinitis in India. Aiming to provide patients a far more convenient, and cost-effective treatment option in the country, Glenmark is currently working on strengthening its respiratory segment, which is the need of the hour. Alok Malik, Group Vice President & Head, India Formulations, Glenmark Pharmaceuticals, Mumbai spoke to BioSpectrum in detail about the growth plans of the company in the allergic rhinitis space. Edited excerpts;
How big is the allergic rhinitis market in India? Who are the key players?
Around 600 million people in the world are suffering from allergic rhinitis (AR). Of this, the incidence of AR in India is around 20 to 30 per cent. The majority of the patients in India suffer from nasal obstruction as a major symptom of AR. The overall AR market in India is divided into two parts: Oral Antihistamines (OAH) valued at Rs 1599 crore and Intranasal Corticosteroids & Comb (Nasal Spray) valued at Rs 280 crore. The total market accounts for around Rs 1879 crore in India. The key players of the nasal spray market include Cipla, Lupin and Zydus.
What are the current challenges facing this market?
In India, Intranasal Corticosteroid (INCs) and combination market is dominated by few players. However, most of the existing brands made available in the market by such players offer high cost of therapy as compared to Oral Antihistamines (Tablets). As, in India, patients have to bear the drug cost on their own, the price of the drug becomes a major factor that impacts treatment adherence.
How do you plan to make a difference in the allergic rhinitis market with Ryaltris-AZ Nasal Spray?
Continue reading your story on the app
Continue reading your story in the magazine
“R&D outsourcing has become a ‘must have' than ‘good-to have' strategy”
Aragen Life Sciences (formerly GVK BIO), a leading contract research and development organisation headquartered in Hyderabad, is marking its transition to a new brand identity in its 20th year. Established in 2001, the company is poised for growth in the outsourced discovery, development, and manufacturing services sector across both large and small molecule platforms with new investments and collaborations. In conversation with BioSpectrum, Manni Kantipudi, Chief Executive Officer, Aragen Life Sciences, Hyderabad reveals more about the company’s recent rebranding and growth plans. Edited excerpts;
Premas Biotech to commercialise VLP vaccine tech against Delta variant
Gurugram-based Premas Biotech has signed a licensing deal with Oravax Medical for the development and commercialisation of its virus-like-particle COVID-19 vaccine technology.
SARS-CoV-2: A Biochemical Treatise on its Past, Present & Future
The SARS-CoV-2 pandemic is unprecedented but equally unprecedented is the contribution of scientists who have helped us in understanding the mechanisms by which it infects human beings and also, developing a variety of vaccines to protect the masses, in a year’s time, which can be called truly groundbreaking. This article gives an overview of the progress made by scientists around the world working round the clock in developing an understanding of the SARS-CoV-2 evolution and COVID-19 disease pathogenesis, and also makes an attempt to suggest the possible ways of coping with this pandemic if we have to co-exist with it forever!
Merck launches Pergoveris Pen for fertility treatment in India
Merck Specialties, the healthcare business of Merck in India, has launched Pergoveris Pen for advanced infertility treatment in India.
How tech innovations impact cardiac care
Cardiac care has seen a transformation over the years with technology playing an important role. Armed with Artificial intelligence (AI) and machine learning (ML), cardiac care providers, with the right technology, have received the right impetus to revolutionise treatment mechanisms. Let us delve into the new technologies which the industry is offering to mankind and decipher the way forward.
GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B
While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others. The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry.
Glenmark ties up with SaNOtize to commercialise COVID-19 nasal spray
Mumbai-based Glenmark Pharmaceuticals and Canadian biotech firm SaNOtize Research & Development Corporation
CEPI prioritises Rift Valley fever vax
Sep 01, Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) has signed an implementing partner agreement with Integrum Scientific (US) as part of its ongoing efforts to combat Rift Valley fever (RVF)—one of its priority diseases with epidemic potential.
3D printing moulds healthcare innovations
Pharmaceuticals, bio-medicine, aviation, and automobiles industries have rapidly adopted 3D printing over the years, worldwide, to develop new solutions and prototypes. It is also helping many industries, healthcare, in particular, increase productivity. Despite all its advantages, 3D printing technology is currently posing a number of challenges in the market such as initial costs, limitation to the metals and plastics used for 3D printing, lack of policy standardisation, etc.
Mynvax Offers ‘Warm Vaccine' For COVID-19
Biotech startup Mynvax, incubated at the Indian Institute of Science (IISc) in Bengaluru, has developed heat-tolerant COVID-19 vaccine formulations.
Building Community Through Education
KIRAN BIR SETHI is changing the experience of childhood in Indian cities through her education curriculum and initiatives to build healthy relationships between students and their communities. Here she is interviewed by KASHISH KALWANI.
Granny Chic Galore!
A homeowner’s holiday décor is an homage to Christmas at her grandma’s house.
NATURAL FOOD: Sources Of Retinol
Retinol considered the queen in skin care as it increases collagen production, which is a very important aspect in delaying skin aging.
INDIANA NOTIFYING 750K AFTER COVID-19 TRACING DATA ACCESSED
Indiana health officials said they are notifying nearly 750,000 state residents that a cybersecurity company “improperly accessed” their personal data from the state’s online COVID-19 contact tracing survey — a description the company disputed as a “falsehood.”
What is My Stereo's Gender?
Readers will recall, distressingly, that I have tried their patience on just about every topic that marginally relates to audio. LP grooves, CD bumps, flat response, boomy bass, warm recordings, cold binary bits—I have waxed philosophically on all of them. Which bring us to today’s audio topic: gender.
One of my closest friends in my hometown had a love marriage, which many considered to be a rebellious act against our small society.
Contentment - THE ART OF REMOVING AND CREATING HABITS
DAAJI continues his series on refining habits, in the light of Patanjali’s Ashtanga Yoga and current scientific and yogic principles and practices. Last month, he explored the first Niyama of purity, shaucha. This month he shares his insights on that pivotal human quality – contentment, which is known in Yoga as santosh.
Carlyle's Goyal Brings India Lessons to Infrastructure, Energy Investing
POOJA GOYAL, 41, brings a unique personal insight to Carlyle Group Inc., where she leads the renewable and sustainable energy team and co-heads the infrastructure group.
Building a Work of Art
To celebrate the release of the 2022 Indian Chief the legend-ary motorcycle company got together two of the world’s most sought after builders, Paul Cox and Keino Sasaki, to customize a bike for celebrated tattoo artist Nikko Hurtado.
Can Bollywood Survive Modi?
Its films have always celebrated a pluralistic India, making the industry—and its Muslim elite—a target of Hindu nationalists.